ESMO Events 2025
ESMO Gastrointestinal Cancers Congress 2025
This important event will bring together leading experts, researchers, and healthcare professionals dedicated to the advancement of gastrointestinal cancers treatment and care.
Through groundbreaking presentations, multidisciplinary tumour boards, controversy sessions, and more, attendees will have the opportunity to delve into the latest research findings, innovative therapeutic strategies, and emerging technologies that are shaping the future of GI cancers treatment.
The programme will cover a wide spectrum of topics, including molecular prevention, diagnosis, precision therapy, and patient-centered care approaches in the treatment of GI malignancies.
Below a collection of papers recently published in ESMO’s premier journals carefully selected to reflect the themes of the meeting.
Annals of Oncology
Neo-adjuvant FOLFOX with and without panitumumab for patients with KRAS-wt locally advanced colon cancer: results following an extended biomarker panel on the FOxTROT trial embedded phase II population☆ J.F. Seligmann, D. Morton, F. Elliott, K. Handley, R. Gray, M. Seymour, B. Glimelius, L. Magill, C.J.M. Williams, P. Quirke, D. Bottomley, H.M. Wood, K. Murakami, A.D. Beggs, N.P. West on behalf of the FOxTROT Collaborative Group
The impact of neoadjuvant therapy in patients with left-sided resectable pancreatic cancer: an international multicenter study E. Rangelova, T.F. Stoop, T.M.E. van Ramshorst, M. Ali, E.A. van Bodegraven, A.A. Javed, D. Hashimoto, E. Steyerberg, A. Banerjee, A. Jain, A. Sauvanet, A. Serrablo, A. Giani, A. Giardino, A. Zerbi, A. Arshad, A.G. Wijma, A. Coratti, A. Zironda, A. Socratous, A. Rojas, A. Halimi, A. Ejaz, A. Oba, B.Y. Patel, B. Björnsson, B.N. Reames, B. Tingstedt, B.K.P. Goh, C. Payá-Llorente, C.D. Del Pozo, C. González-Abós, C. Medin, C.H.J. van Eijck, C. de Ponthaud, C. Takishita, C. Schwabl, C. Månsson, C. Ricci, C.A. Thiels, D. Douchi, D.L. Hughes, D. Kilburn, D. Flanking, D. Kleive, D.S. Silva, B.H. Edil, E. Pando, E. Moltzer, E.F. Kauffman, E. Warren, E. Bozkurt, E. Sparrelid, E. Thoma, E. Verkolf, F. Ausania, F. Giannone, F.J. Hüttner, F. Burdio, F.R. Souche, F. Berrevoet, F. Daams, F. Motoi, G. Saliba, G. Kazemier, G. Roeyen, G. Nappo, G. Butturini, G. Ferrari, G. Kito Fusai, G. Honda, G. Sergeant, H. Karteszi, H. Takami, H. Suto, I. Matsumoto, I. Mora-Oliver, I. Frigerio, J.M. Fabre, J. Chen, J.G. Sham, J. Davide, J. Urdzik, J. de Martino, K. Nielsen, K. Okano, K. Kamei, K. Okada, K. Tanaka, K.J. Labori, K.E. Goodsell, L. Alberici, L. Webber, L. Kirkov, L. de Franco, M. Miyashita, M. Maglione, M. Gramellini, M. Ramera, M.J. Amaral, M. Ramaekers, M.J. Truty, M.A. van Dam, M.W.J. Stommel, M. Petrikowski, M. Imamura, M. Hayashi, M. D’Hondt, M. Brunner, M.E. Hogg, C. Zhang, M.Á. Suárez-Muñoz, M.D. Luyer, M. Unno, M. Mizuma, M. Janot, M.A. Sahakyan, N.B. Jamieson, O.R. Busch, O. Bilge, O. Belyaev, O. Franklin, P. Sánchez-Velázquez, P. Pessaux, P.S. Holka, P. Ghorbani, R. Casadei, R. Sartoris, R.D. Schulick, R. Grützmann, R. Sutcliffe, R. Mata, R.B. Patel, R. Takahashi, S. Rodriguez Franco, S.S. Cabús, S. Hirano, S. Gaujoux, S. Festen, S. Kozono, S.K. Maithel, S.M. Chai, S. Yamaki, S. van Laarhoven, J.S.D. Mieog, T. Murakami, T. Codjia, T. Sumiyoshi, T.M. Karsten, T. Nakamura, T. Sugawara, U. Boggi, V. Hartman, V.E. de Meijer, W. Bartholomä, W. Kwon, Y.X. Koh, Y. Cho, Y. Takeyama, Y. Inoue, Y. Nagakawa, Y. Kawamoto, Y. Ome, Z. Soonawalla, K. Uemura, C.L. Wolfgang, J.Y. Jang, R. Padbury, S. Satoi, W. Messersmith, J.W. Wilmink, M. Abu Hilal, M.G. Besselink, M. Del Chiaro, for the European Consortium on Minimally Invasive Pancreatic Surgery (E-MIPS) the International Consortium on Advanced Pancreatic Surgery
Survival among patients treated with total mesorectal excision or selective watch-and-wait after total neoadjuvant therapy: a pooled analysis of the CAO/ARO/AIO-12 and OPRA randomized phase II trials H. Williams, E. Fokas, M. Diefenhardt, C. Lee, F.S. Verheij, D.M. Omer, S.T. Lin, R.F. Dunne, J. Marcet, P. Cataldo, B. Polite, P. Piso, B. Polat, H. Dapper, M. Ghadimi, R.D. Hofheinz, L.-X. Qin, L.B. Saltz, A.J. Wu, M.J. Gollub, J.J. Smith, M.R. Weiser, C. Rödel, J. Garcia-Aguilar, on behalf of the German Rectal Cancer Study Group and the OPRA Consortium
ESMO Open
Phase II study of elraglusib (9-ING-41), a GSK-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel in previously untreated metastatic pancreatic cancer D. Mahalingam, A. Saeed, S.F. Powell, M. Huerta, V. Sahai, A.L. Coveler, E.J. Davis, N. Steeghs, M. Mulcahy, A.G. Raufi, L. Cavalcante, A. Cervantes, J. Berlin, T. Weisskittel, A. Ugolkov, A.P. Mazar, W. Mikrut, S. Smith, F.J. Giles, B.A. Carneiro
Health-related quality of life analysis of the LEAP-002 study of lenvatinib plus pembrolizumab versus lenvatinib as first-line treatment for advanced hepatocellular carcinoma R.S. Finn, M. Kudo, P. Merle, T. Meyer, S. Qin, M. Ikeda, R. Xu, J. Edeline, B.-Y. Ryoo, Z. Ren, A.-L. Cheng, P.R. Galle, S. Kaneko, H. Kumada, S. Kamble, J.M. Norquist, K. Mody, A. Wang, L. Dubrovsky, J.M. Llovet
Uncovering PD-L1 among immune cell predictive biomarkers and actionable genetic alterations in anal squamous-cell carcinomas in the era of immunotherapy G. Sharma, Y. Baca, A.F. Shields, A. Prakash, B.A. Weinberg, A. Saeed, S. Goel, A. Abdalla, M. Oberley, J. Xiu, J. Hwang, E.S. Antonarakis, V.K. Chiu, E. Lou
Immuno-Oncology and Technology
A phase II study of nivolumab, ipilimumab, and radiation in combination with influenza vaccine in patients with pancreatic cancer (INFLUENCE) I.M. Chen, S. Theile, K. Madsen, J.S. Johansen, T. Lorentzen, A. Toxværd, E. Høgdall, I.M. Svane, D. Nielsen
Potentiating intratumoral therapy with immune checkpoint inhibitors: shifting the paradigm of multimodality therapeutics B.E. Nelson, A. Naing, S. Fu, R.A. Sheth, R. Murthy, S. Piha-Paul
ESMO Gastrointestinal Oncology
Genomic heterogeneity and clinical implications in gastrointestinal neuroendocrine carcinoma: MYC and KRAS as predictive biomarkers T. Ozato, Y. Kono, H. Yamamoto, A. Hirasawa, D. Ennishi, S. Tomida, S. Toyooka, M. Otsuka
Long-term outcome after perioperative chemotherapy and surgery for gastro-esophageal adenocarcinoma S. Shim, A.C. Larsen, L. Bæksgaard, P. Pfeiffer, M. Nordsmark, J.R. Sørensen, A.K. Motavaf, M. Ladekarl
Quantitative benefit–risk assessment of data from the phase III ClarIDHy study of ivosidenib versus placebo in patients with mIDH1 cholangiocarcinomaJ.W. Valle, G.K. Abou-Alfa, R.K. Kelley, M.A. Lowery, R.T. Shroff, Y. Bian, G. Saint-Hilary, H. Liu, Z. Teng, Z. Hua, C. Gliser, A. Vogel, M.M. Javle
ESMO Real World Data and Digital Oncology
Local and central testing for HER2, PD-L1, MSI/MMR, EBV, and CLDN18.2 in advanced gastric cancer: results from the SAPHIR registry☆ K. Potthoff, H. Bläker, T. Dechow, A. Binninger, K. Ringwald, R. de Buhr, E. von der Heyde, M.-O. Zahn, A. Nusch, S. Dörfel, H. Schulz, I. Haffner, A.K. Höhn, A. Monecke, S. Lorenzen, A. Reinacher-Schick, M. Jänicke, F. Lordick
Real-world treatment patterns and survival in patients with synchronous and metachronous metastatic colorectal cancer in the Netherlands M.A.G. Elferink, F.N. van Erning, F.C. Sijtsma, L.B. Valkenburg-van Iersel, M.L. Wumkes, J.M.L. Roodhart, G.R. Vink
Advanced risk signature analysis of inflammation markers in predicting prostate cancer using the Swedish Apolipoprotein-related MOrtality RISk (AMORIS) cohort G. George, M. Rowley, A.C.C. Coolen, A. Santa Olalla, N. Hammar, M. Feychting, S.N. Karagiannis, D. Enting, M. Van Hemelrijck
ESMO affiliated journals
EORTC consensus recommendations on the optimal management of colorectal cancer liver metastases Giacomo Bregni, Richard Adams, Reto Bale, Maria A Bali, Irene Bargellini, Lennart Blomqvist, Gina Brown, Chiara Cremolini, Pieter Demetter, Timm Denecke, Anthony Dohan, Cristina Dopazo, Elena Elez, Serge Evrard, Roger Feakins, Matthias Guckenberger, Marianne Gronlie Guren, Maria Hawkins, Anne Hoorens, Emmanuel Huguet, Martijn Intven, Thibaud Koessler, Wolfgang G Kunz, Florian Lordick, Valerio Lucidi, Andreas H Mahnken, Hassan Malik, Philippe Martinive, Murielle Mauer, Alejandra Méndez Romero, Iris Nagtegaal, Franco Orsi, Wim JG Oyen, Olivier Pellerin, Marco Rengo, Jens Ricke, Alexis Ricoeur, Angela Riddell, Maxime Ronot, Marta Scorsetti, Jenny Seligmann, Christine Sempoux, Kieran Sheahan, Stefan Stättner, Magali Svrcek, Julien Taieb, Nick West, Lucjan Wyrwicz, Christoph J Zech, Markus Moehler, Francesco Sclafani
The present and the future of immunotherapy in hepatocellular carcinoma and biliary tract cancers Giuseppe Cabibbo, Lorenza Rimassa, Angela Lamarca, Gianluca Masi, Bruno Daniele, David James Pinato, Andrea Casadei-Gardini
ESMO's Journal Portfolio
While diverse in nature and in content, these journals offer ESMO members and the oncology community a highly visible platform to publish important scientific studies, and a highly credible source for educational updates. Elsevier is the proud publisher of Annals of Oncology, Immuno-Oncology and Technology (IOTECH), ESMO Open, ESMO Gastrointestinal Oncology, ESMO Real World Data and Digital Oncology, ESMO Rare Cancers, and ESMO Affiliated Journals The Breast, Lung Cancer, Cancer Treatment Reviews and Clinical Lymphoma Myeloma and Leukemia.
